This multi-center, observational study will evaluate the clinical practice patterns, efficacy and safety of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Data will be collected from each eligible patient initiated on RoActemra/Actemra treatment by their treating physician according to approved label for up to 12 months from start of treatment.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01565122?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
